De-risking rare disease acquisitions: a win–win–win for patients, biotech and investors
De-risking rare disease acquisitions: a win–win–win for patients, biotech and investors
About this item
Full title
De-risking rare disease acquisitions: a win–win–win for patients, biotech and investors
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Nature reviews. Drug discovery, 2024-01, Vol.23 (1), p.10-11
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Alternative Titles
Full title
De-risking rare disease acquisitions: a win–win–win for patients, biotech and investors
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2899372079
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2899372079
Other Identifiers
ISSN
1474-1776,1474-1784
E-ISSN
1474-1784
DOI
10.1038/d41573-023-00190-x
